Blog

Nelson Advisors Partner Lloyd Price has been invited to judge UCL's fourth annual Dragons’ Den Competition at the Global Business School for Health.The Dragons’ Den Competition is open to all GBSH students, inviting them to develop innovative business ideas to improve healthcare.Ideas span the full health ecosystem, including digital health, pharmaceuticals, biotechnology, healthcare and hospital management, patient safety, bioscience and public health.Across four rounds, students refine their concepts before presenting them in the live final. Our Dragons are experienced investors and serial entrepreneurs from across the health sector, bringing commercial insight and real-world expertise.All finalists receive funding to support their ideas. The winning team is awarded £4,000, shared between group members, along with a year of expert mentoring.The DragonsDr Vanessa Dekou PhD, MBA, Managing Director of Clinical Services International (CSI)Dr Ruth Weir Ph.D., Head of Entrepreneurship at UCLLloyd Price, Partner and Co-Founder of Nelson AdvisorsLars B Andersen, CEO of My NametagsSource: <a href="https://www.ucl.ac.uk/population-health-sciences/events/2026/jun/dragons-den-grand-final-24-june-2026" data-mce-href="https://www.ucl.ac.uk/population-health-sciences/events/2026/jun/dragons-den-grand-final-24-june-2026">https://www.ucl.ac.uk/population-health-sciences/events/2026/jun/dragons-den-grand-final-24-june-2026</a>

Nelson Advisors Partner Lloyd Price has been invited to judge UCL's fourth annual Dragons’ Den Competition at the Global Business School for Health

Healthcare technology stands out as one of the strongest themes in the 2026 CNBC Disruptor 50, but it is now framed almost entirely through an AI and data infrastructure lens rather than classic digital health point solutions. Below are the key takeaways specifically relevant to healthcare and health-adjacent tech.Dominance of AI-Native Infrastructure CNBC highlights that 43 of the 50 companies explicitly identify AI as core to their disruptive strategy, making AI the default operating layer across sectors including healthcare. The topline narrative is that value creation is concentrating in foundational and horizontal AI platforms (Anthropic, OpenAI, Databricks, etc.), which then power domain-specific applications in areas like diagnostics, care coordination, and payer/provider tooling. Healthcare as a Secondary but Critical Use Case The methodology piece notes that many Disruptor 50 companies are not labeled “healthcare” but have healthcare as one of their primary application domains (e.g., data platforms, workflow AI, security and infra tools that sell into health systems and payers). This reinforces a shift from pure-play digital health brands towards cross-vertical tech (AI infra, cybersecurity, data clouds, automation platforms) that monetise healthcare as a high-value vertical rather than a standalone category. Continued Presence of Care Delivery and Patient Platforms CNBC’s criteria specifically calls out healthcare as a focus area, and the 2026 list maintains representation of care delivery and patient-platform disruptors, including oncology care coordination platforms such as Thyme Care. These companies emphasise risk-bearing models, partnerships with payers/employers and measurable reductions in total cost of care, very much aligned with value-based care economics. Oncology and High-Acuity Care as Beachheads Thyme Care’s inclusion underscores oncology as a leading beachhead for tech-enabled care, with platforms taking financial accountability for outcomes and cost in partnership with payers and risk-bearing providers. The framing is less about “tele-oncology” and more about end-to-end oncology navigation, data-driven risk stratification, and closed-loop coordination across providers, payers, and patients. AI-First Clinical and Operational Intelligence The selection methodology stresses that scoring favored companies with defensible data moats and AI-driven products, explicitly mentioning health-related applications among the verticals assessed. For healthcare, this means preference for businesses that embed AI into core workflows (triage, prediction, routing, coding, utilization management) rather than offering bolt-on analytics or generic dashboards. Geographic Gravity: Bay Area AI, Global Healthcare Deployment 18 of the 50 companies are in the Bay Area, with 14 headquartered in San Francisco, and nearly half of all companies are based in California. For healthcare buyers in Europe and other regions, this implies that critical AI tooling for future healthtech stacks is largely being built in the Bay Area but will be distributed globally across payers, providers, and life science partners. Capital Concentration and Scale Expectations CNBC notes that the 2026 cohort collectively represents about 2.4 trillion dollars in valuation and 337 billion dollars in funding, nearly triple the funding base of the prior year. The top five AI platforms alone account for close to 2 trillion dollars of that value, which sets a high bar for healthcare-native startups and pushes many healthtech plays towards partnering with or building on these AI “supermajors.” Implications for Healthcare and HealthTech Strategy The list signals that future healthcare disruption is expected to come from:AI-native infra providers expanding into healthcare, Risk-bearing care platforms in oncology and other high-cost conditions, and Data and workflow companies that can prove cost and outcome impact in payer–provider networks.Source: <a href="https://www.cnbc.com/2026/05/19/2026-cnbc-disruptor-50-rankings-full-list-companies.html" data-mce-href="https://www.cnbc.com/2026/05/19/2026-cnbc-disruptor-50-rankings-full-list-companies.html">https://www.cnbc.com/2026/05/19/2026-cnbc-disruptor-50-rankings-full-list-companies.html</a>

Healthcare Technology stands out as one of the strongest themes in the 2026 CNBC Disruptor 50

Nelson Advisors are proud to have been invited for the 3rd year in a row to speak and join the HealthTech panels at the Healthcare Summit 2026 in September 2026.Healthcare Summit 2026Healthcare Summit is the UK’s leading conference for investors, advisors and operators in healthcare.This is your opportunity to get a comprehensive update on the state of the market and hear from the key players in health and social care, all in one day at London’s Business Design Centre.Who attends? 1,000+ people attend the Healthcare Summit for a day of high-quality content, discussion and networking.Attendees include:Health Groups/Executives Care Owners/Directors Investors/Banking/Private Equity Advisors Suppliers &nbsp; Why attend?Healthcare Summit is organised by Nexus Media Group, the publishers of market-leading titles HealthInvestor, Caring Times and Healthcare Property. We’ve truly got our finger on the pulse of health and social care, enabling us to assemble a leading agenda of essential content.The conference agenda offers:Thought leadership from influential speakers Panel discussions and roundtables with industry leaders The latest market updates, trends and data Analysis from the experts and forecasts for the future Insights into challenges and opportunities within the sector Sessions focused on areas including investment, M&amp;A, health tech, care homes, hospitals, property and moreSource: <a href="https://healthcare-summit.co.uk" data-mce-href="https://healthcare-summit.co.uk">https://healthcare-summit.co.uk</a>

Nelson Advisors invited to join the HealthTech panels at the Healthcare Summit 2026

European healthcare M&amp;A is undergoing a structural transformation that extends well beyond deal volumes and capital flows. The defining shift of the 2025–2026 cycle is not macroeconomic, it is epistemological: the question of who is best qualified to advise on the sale, acquisition and strategic positioning of healthcare technology assets has been fundamentally reopened. &nbsp;&nbsp; For three decades, the architecture of healthcare M&amp;A advisory was dominated by generalist bulge-bracket institutions, Goldman Sachs, J.P. Morgan, Morgan Stanley, Rothschild, whose authority derived from balance-sheet capability, broad institutional relationships and league-table prestige.&nbsp; &nbsp;&nbsp; In 2026, that architecture remains intact for large-cap, cross-border mega-deals exceeding €500 Million. But for the far larger universe of founder-led, venture-backed and growth-stage HealthTech, MedTech, FemTech and Healthcare AI companies, the middle market that generates the majority of European deal volume, a new class of advisor has emerged and, in many sub-sectors, taken primacy. &nbsp;&nbsp; They are called Founder Bankers: former entrepreneurs and clinicians who built, scaled and exited their own healthcare technology ventures before transitioning into the advisory role. The model fuses deep operational pedigree with sophisticated investment banking methodology, offering what traditional finance cannot easily replicate, fluency in the lived experience of company-building, clinical pathway navigation and the psychological complexity of founder exit events.​​ &nbsp;&nbsp; This report analyses the structural drivers of this advisory evolution, the anatomy of the Founder Banker archetype, the market dynamics reinforcing its ascendancy across HealthTech, MedTech, FemTech and Healthcare AI, and the strategic outlook for founders, investors and acquirers navigating this new landscape.<a href="https://www.healthcare.digital/single-post/the-operator-led-evolution-in-european-healthcare-m-a-the-rise-of-founder-bankers-in-healthtech-me">https://www.healthcare.digital/single-post/the-operator-led-evolution-in-european-healthcare-m-a-the-rise-of-founder-bankers-in-healthtech-me</a>

The Anatomy of the Founder Banker, A New Professional Archetype

FemTech is no longer a niche category within healthcare innovation. Conditions such as menopause, endometriosis, and PCOS are gaining increasing recognition as major health concerns and areas with significant unmet market demand. PCOS alone affects an estimated 6–13% of women of reproductive age globally.At the same time, women’s health technologies spanning diagnostics, mental health, and preventative care are attracting growing attention from founders, investors, and healthcare systems worldwide. Yet despite increasing momentum, many startups continue to face the same challenge: how do you scale meaningful innovation into sustainable healthcare businesses?This question sat at the center of a recent expert session hosted through the QSTP × Merck FemTech Accelerator, where founders, researchers, and ecosystem experts gathered to discuss the realities shaping today’s FemTech landscape. Led by Julie Pelta, Director of FemTech &amp; MedTech at Nelson Advisors and Health &amp; Life Sciences Assessor at Innovate UK, the session explored the opportunities, bottlenecks, and operational challenges defining the next phase of women’s health innovation.One message emerged consistently throughout the discussion: innovation alone is not enough.Source: <a href="https://qstp.qa/blog/the-state-of-femtech-scaling-beyond-the-hype/">https://qstp.qa/blog/the-state-of-femtech-scaling-beyond-the-hype/</a>

Nelson Advisors invited to Chair the QSTP × Merck FemTech Accelerator 'State of FemTech' session

Key Metrics for a HealthTech and MedTech company to raise a Series A round in Europe in today's environmentThe European healthtech and medtech sectors have entered a phase of disciplined maturity, transitioning away from the venture subsidised experimentation of the early 2020s toward an era characterised by industrialisation and regulatory Darwinism.&nbsp; &nbsp;&nbsp; In the current market environment of 2025 and 2026, the criteria for a successful Series A funding round have shifted fundamentally. Investors no longer prioritise raw user acquisition or speculative growth; instead, they demand a rigorous demonstration of clinical utility, regulatory fortitude and a clear line of sight to measurable return on investment (ROI) within strained healthcare systems.&nbsp; &nbsp;&nbsp; This structural transformation is driven by elevated costs of capital and the simultaneous enforcement of complex legislative frameworks, including the EU Medical Device Regulation (MDR), the In Vitro Diagnostic Regulation (IVDR), and the EU AI Act.&nbsp; &nbsp;&nbsp; For a startup to secure Series A capital today, it must navigate a landscape where capital is highly polarised, concentrating in a narrow cohort of "de-risked" assets that can prove their integration into clinical pathways and their ability to alleviate systemic burdens.<a href="https://www.healthcare.digital/single-post/key-metrics-for-a-healthtech-and-medtech-company-to-raise-a-series-a-round-in-europe-in-today-s-envi" data-mce-href="https://www.healthcare.digital/single-post/key-metrics-for-a-healthtech-and-medtech-company-to-raise-a-series-a-round-in-europe-in-today-s-envi">https://www.healthcare.digital/single-post/key-metrics-for-a-healthtech-and-medtech-company-to-raise-a-series-a-round-in-europe-in-today-s-envi</a>Key Metrics for a HealthTech and MedTech company to raise a Series B round in Europe in today's environmentThe European healthcare technology and medical technology sectors have reached a definitive inflection point in 2026, transitioning from a period of speculative experimentation into what industry analysts categorise as the era of industrial maturity. This evolution is characterised by a "flight to quality," where the market has bifurcated into a high-conviction environment for category leaders and a severe capital squeeze for mid-stage ventures that fail to demonstrate immediate, systemic value.&nbsp; &nbsp;&nbsp; As the aggregate data suggests a resilient recovery, evidenced by European digital health funding rising to an estimated $6.2 Billion in 2025, the underlying mechanics of the Series B round reveal a persistent "Series B Gap," with the time to close funding rounds now approaching 10 to 12 months. Investors are no longer captivated by technological promise in isolation; instead, they prioritise deep integration into clinical workflows, robust unit economics and a transparent path to profitability.<a href="https://www.healthcare.digital/single-post/key-metrics-for-a-healthtech-and-medtech-company-to-raise-a-series-b-round-in-europe-in-today-s-envi">https://www.healthcare.digital/single-post/key-metrics-for-a-healthtech-and-medtech-company-to-raise-a-series-b-round-in-europe-in-today-s-envi</a>Key Metrics for a HealthTech and MedTech company to raise a Series C round in Europe in today's environmentThe European healthcare technology and medical technology landscape has entered a profound inflection point as it moves through 2025 and into 2026. This period is increasingly defined by a transition from the speculative fragmentation and "growth-at-all-costs" mindset of the early 2020s to a disciplined, professionalised era termed industrial maturity.&nbsp; &nbsp;&nbsp; For companies preparing to raise a Series C funding round in this environment, the requirements have shifted from simple user acquisition or technological promise to a rigorous demonstration of unit economics, regulatory resilience, clinical validation and structural integration into healthcare systems.&nbsp; &nbsp;&nbsp; The defining thesis for venture capital and private equity in 2026 is the industrialisation of the sector, where valuations are no longer detached from the realities of reimbursement and clinical outcomes. This shift is necessitated by an elevated cost of capital and a "Great Capital Polarisation" that favours de-risked category leaders over smaller, unprofitable ventures.<a href="https://www.healthcare.digital/single-post/key-metrics-for-a-healthtech-and-medtech-company-to-raise-a-series-c-round-in-europe-in-today-s-envi">https://www.healthcare.digital/single-post/key-metrics-for-a-healthtech-and-medtech-company-to-raise-a-series-c-round-in-europe-in-today-s-envi</a>To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors

Blog

Nelson Advisors Partner Lloyd Price has been invited to j...

Healthcare Technology stands out as one of the strongest ...

Nelson Advisors invited to join the HealthTech panels at ...

The Anatomy of the Founder Banker, A New Professional Arc...

Nelson Advisors invited to Chair the QSTP × Merck FemTech...

Key Metrics for HealthTech and MedTech companies to raise...